9 Meters Biopharma (NMTRQ) 10-Q2023 Q1 Quarterly report

Filed: 15 May 23, 5:18pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: absolute, added, analog, antagonist, baby, beneficially, Black, clarity, classification, CMO, Codification, collectively, component, constructed, construction, consumption, cover, covered, COVID, degree, degressive, derecognized, directionally, Distinguishing, documentation, earliest, earned, eleven, employed, enable, enforcing, extinguishment, float, fluid, forbear, forbearance, freestanding, Gattex, half, higher, indexed, input, interaction, interruption, lack, landlord, lieu, long, maintenance, maximize, mice, occurrence, oversee, oversight, paper, partial, prerequisite, produce, prohibit, prohibited, promote, promoting, QW, recurrent, repayment, request, retention, role, runway, settlement, stockholder, submit, subsidiary, suffer, surface, tenant, thereof, unamortized, unexercised, uptake, vii, viii, workforce, young

Removed: abdominal, absent, absorb, absorption, achieved, acquire, activation, administered, Administration, adult, alternative, analogue, annum, APAZA, appetite, attempting, avoid, began, Blair, bore, care, carried, CeD, CeDLara, chain, Chairman, Cholangiopancreatography, Citigroup, Clarifying, clinically, closely, coherent, compounding, conferred, consultation, coordinating, correlated, dedicated, delayed, dependency, depending, diagnose, diet, dilution, directional, distancing, dosing, easily, economy, emergency, entity, escalating, Europe, evaluable, excellent, exenatide, experienced, FASB, feature, fewer, frequency, gastric, generic, guidance, Gustav, healthcare, high, holdback, Imaging, impacted, impairment, implementing, increasing, inform, instrument, intangible, intervention, intrinsic, launched, length, limiting, linker, Magnetic, managed, marketing, meaningful, Medicare, metabolic, mild, monitoring, movement, nausea, negatively, objective, occur, Omicron, onset, ordered, Organization, outbreak, pace, Pancreatic, participant, percentage, permitted, personal, prevalence, problem, profiling, promissory, protective, protein, purpose, qualified, quality, recovery, reducing, rely, remotely, repeated, Repligen, Resonance, restricting, routine, safe, satisfied, satisfy, Seachaid, Secretin, sentiment, separately, slower, social, supplementation, survey, survive, tangible, tax, tolerability, tolerated, Topic, transient, transit, transparency, travel, treat, ultimate, uncertain, underwriting, unforeseen, unsecured, utilized, utilizing, variable, variant, vomiting, water, widely, William, work, working, World

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

NMTRQ similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

I, John Temperato, Chief Executive Officer of 9 Meters Biopharma, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1) the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.


		By:	/s/ John Temperato
Date:	May 15, 2023		John Temperato
			Chief Executive Officer
			(Principal Executive Officer)

This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.